Frontlight ResearchEarly access
Multiple myeloma trials in Spain
75 of 81 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Pamplona, Salamanca
- Age
- 18 years and over
- People
- 165 worldwide
- Run by
- K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00 - Phase 3Not yet taking people in SpainA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville
- Age
- 18 years to 130 years
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - Phase 1Active, not recruitingA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - Phase 3Taking peopleA Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
- Where
- Badalona, Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla
- Age
- 18 years and over
- People
- 206 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-523815-12-00 - Phase 2/3Active, not recruitingA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Where
- Badalona, Barcelona, Las Palmas De Gran Canaria, León, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Valencia
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00 - Phase 2Enrolling by invitationInternational Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Badalona, Madrid, Pamplona, Salamanca, Santander, Seville
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989 - Phase 3Taking peopleA Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- A Coruña, Badalona, Barcelona, Cáceres, Donostia, Granada, Jerez de la Frontera, León, Lugo, Madrid, Málaga, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01 - Phase 3Not yet taking people in SpainSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Badalona, Barcelona, Elche, Madrid, Santander
- Age
- 18 years and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - Phase 2Not yet taking people in SpainMulticenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
- Where
- Albacete, Alicante, Badalona, Barcelona, Gijón, Granada, Las Palmas De Gran Canaria, L'hospitalet De Llobregat, Lugo, Madrid, Marbella, Murcia, Oviedo, Palma, Pamplona, Salamanca, Santander, Valencia, Vitoria
- Age
- 18 years and over
- People
- 60
- Run by
- Fundacion PETHEMA
See details and how to join2026-526352-31-00 - Phase 3Taking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Madrid, Marbella, Palma, Salamanca, Valencia
- Age
- 18 years and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - Phase 3Not yet taking people in SpainA trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Badalona, Barcelona, Madrid, Murcia, Salamanca, Santander, Sevilla
- Age
- 18 years and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00 - No phaseTaking peopleEffects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
- Where
- Madrid
- Age
- 18 years and over
- People
- 32
- Run by
- Universidad Complutense de Madrid
See details and how to joinNCT07312942 - No phaseTaking peopleEffects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
- Where
- Madrid
- Age
- 18 years and over
- People
- 26
- Run by
- Universidad Complutense de Madrid
See details and how to joinNCT07376733 - Phase 3Taking peopleA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Badalona, Cáceres, Madrid, Pamplona, Valencia, Clinica Universidad De Navarra, Hospital Universitario Quironsalud Madrid
- Age
- 18 years and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00 - Phase 3Taking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
- Age
- 18 years and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - Phase 2Taking peopleA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Where
- Badalona, Barcelona, Jerez de la Frontera, Madrid, Murcia, Pozuelo de Alarcón, Salamanca
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00 - Phase 1Taking peopleA Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Where
- Barcelona, Salamanca
- Age
- 18 years and over
- People
- 276 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00 - Phase 3Taking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - Phase 2Enrolling by invitationLong-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
- Where
- Barcelona
- Age
- 1 year and over
- People
- 500 worldwide
- Run by
- Autolus Limited
See details and how to joinNCT03628612 - Phase 1/2CompletedStudy to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Murcia, Palma, Sevilla
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00 - Phase 3Taking peopleA long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Barcelona
- Age
- 18 years and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 - Phase 2Taking peoplePhase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
- Where
- Barcelona, León, Madrid, Málaga, Pamplona, Valencia
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-524793-42-00 - Phase 3Not yet taking people in SpainA trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, Sevilla, Valencia
- Age
- 18 years and over
- People
- 234 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524014-29-00 - Phase 1/2SuspendedA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Salamanca, Santander
- Age
- 18 years and over
- People
- 62 worldwide
- Run by
- Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00 - Phase 1Not yet taking people in SpainA Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
- Where
- Barcelona, Salamanca, Sevilla
- Age
- 18 years and over
- People
- 25 worldwide
- Run by
- TOLREMO therapeutics AG
See details and how to join2025-523536-39-00